This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Top-Ranked ETFs & Stocks to Feast on Thanksgiving and After
by Sanghamitra Saha
According to the Stock Trader's Almanac, stocks normally offer solid returns on the Wednesday before Thanksgiving and the Friday after combined.
MMSI Stock Down Despite Latest Positive Data From WRAPSODY WAVE Trial
by Zacks Equity Research
The significant improvement in patency rates for AVG patients via Merit Medical's WRAPSODY device is expected to enhance patients' vascular access survival.
Premier, Inc. (PINC) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Premier (PINC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights include Cencora, Raymond James and Cintas
by Zacks Equity Research
Cencora, Raymond James and Cintas have been highlighted in this Screen of The Week article.
Why Cencora (COR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Scoop up These 3 GARP Stocks to Receive Handsome Returns
by Vasundhara Sawalka
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. COR, RJF and CTAS are some stocks that hold promise.
Cencora Rallies 19.7% Year to Date: What's Driving the Stock?
by Zacks Equity Research
COR is gaining traction from the robust U.S. Healthcare Solutions segment, which raises optimism about the stock.
MCK Stock Down Despite Latest Partnership to Boost SCD Treatment
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's cell and gene therapies business is expected to give patients improved treatment options for SCD.
Patterson Companies Stock Up Following Latest Partnership Extension
by Zacks Equity Research
PDCO's latest agreement with PDS Health to extend their deal is likely to streamline operations, optimize efficiency and maximize profitability.
Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
by Zacks Equity Research
Here is how Cencora (COR) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Medtronic Q2 Earnings and Revenues Top, Stock Down on Trimmed '25 View
by Zacks Equity Research
MDT delivers diversified growth across all its segments in the second quarter of fiscal 2025.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Cencora (COR) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora Q4 Earnings & Revenues Beat Estimates, Margins Decline Y/Y
by Zacks Equity Research
COR's fourth-quarter fiscal 2024 results showcase a strong segmental performance.
Here's Why Cencora (COR) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cencora (COR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cencora (COR) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Cencora (COR) delivered earnings and revenue surprises of 4.05% and 1.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Cencora to Report Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
COR's fiscal fourth-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.
Cencora (COR) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Earnings Preview: AMN Healthcare Services (AMN) Q3 Earnings Expected to Decline
by Zacks Equity Research
AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cencora (COR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.